Franco M. Muggia, M.D.; Peter A. Cassileth, M.D.; Frederick A. Flatow, M.D.; Alfred A. Gellhorn, M.D., F.A.C.P.; George A. Hyman, M.D., F.A.C.P.; Manuel Ochoa Jr., M.D.
This content is PDF only. Please click on the PDF icon to access.
The observation that progestational agents alone or combined with estrogens might be useful in the management of cancer led to the treatment of 36 patients (34 women and 2 men) with disseminated breast cancer with medroxyprogesterone acetate (Provera®). Patients were selected from two groups: In one, relapse had occurred after treatment with ablative surgery or conventional hormonal and chemotherapeutic agents; in the other, primary estrogen therapy was limited by intolerance or cardiovascular disease. Provera (100 mg) was administered intramuscularly three times weekly or by mouth daily for at least 5 weeks.
Of the 27 patients receiving adequate treatment, 7 had
Learn more about subscription options.
Register Now for a free account.
Muggia FM, Cassileth PA, Flatow FA, Gellhorn AA, Hyman GA, Ochoa M. Treatment of Breast Cancer with Medroxyprogesterone.. Ann Intern Med. 1967;66:1066. doi: 10.7326/0003-4819-66-5-1066_1
Download citation file:
Published: Ann Intern Med. 1967;66(5):1066.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only